Pfizer’s Dimitry Nuyten Jumps to Aduro for Chief Medical Officer Job

Posted by |2019-04-22T14:52:24-07:00April 22nd, 2019|

Aduro Biotech (NASDAQ: ADRO) has appointed Dimitry Nuyten to serve as its chief medical officer. Nuyten comes to Berkeley, CA-based Aduro from Pfizer (NYSE: PFE), where he was vice president and immuno-oncology clinical development leader. Prior to Pfizer, Nuyten was an executive at Bristol-Myers Squibb (NYSE: BMY). Earlier this year, Aduro announced a corporate restructuring […]

Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Posted by |2019-04-22T03:30:07-07:00April 19th, 2019|

Persistence and perseverance were the themes of two of our top stories this week. First there’s the story of Nationwide Children’s Hospital. The Columbus, Ohio, hospital chose to invest in gene therapy when the field was in its darkest days. After some ups and downs, the team it put in place helped advance some of […]

KSQ Therapeutics Taps Blueprint’s Wolf for Chief Medical Officer

Posted by |2019-04-18T14:32:48-07:00April 18th, 2019|

KSQ Therapeutics has appointed Beni Wolf to serve as chief medical officer. Wolf joins Cambridge, MA-based KSQ from Blueprint Medicines, where he was senior vice president, clinical development. His experience also includes posts at Merrimack Pharmaceuticals (NASDAQ: MACK), ImmunoGen (NASDAQ: IMGN), Amgen (NASDAQ: AMGN), and Genentech. Cambridge, MA-based KSQ also named Douglas Pagán chief financial […]

$100M For Talaris Gives Surgeon a Shot to Reinvent Organ Transplants

Posted by |2019-04-18T01:55:26-07:00April 18th, 2019|

When Novartis dissolved its gene and cell therapy unit a few years ago, a bunch of projects the Swiss pharma giant had incubated were tossed aside. One of them was the work of surgeon Suzanne Ildstad, who has spent decades trying to develop a new way to improve the health outcomes of patients who need […]

Former Jazz Pharma Exec Vanhove Named Surrozen Chief Medical Officer

Posted by |2019-04-16T14:22:02-07:00April 16th, 2019|

Trudy Vanhove has joined regenerative medicine biotech Surrozen as chief medical officer. Vanhove most recently worked at Jazz Pharmaceuticals (NASDAQ: JAZZ), where she was vice president of medical affairs as well as vice president, head of R&D search and evaluation. South San Francisco-based Surrozen is developing drugs that activate and regulate tissue repair in the […]

Alzheimer’s, Gene Therapy & More: Agenda For “What’s Hot” on May 21

Posted by |2019-04-16T02:25:20-07:00April 16th, 2019|

The gene therapy boom. The frustration of failure after failure in Alzheimer’s disease. The critical interplay between venture firms and “crossover” investors in a volatile, unpredictable macro-environment. The growing need for (and role of) diversity initiatives within the life sciences community—and the personal stories behind them. These are just some of the topics Xconomy will […]

Alnylam Makes Case For 2nd RNAi Drug at Big Liver Disease Meeting

Posted by |2019-04-15T03:30:08-07:00April 12th, 2019|

The “attacks,” as they’re known, are debilitating and even possibly fatal. A patient with the ultra-rare genetic disease acute hepatic porphyria (AHP) is struck with excruciating abdominal pain and rushes to a doctor’s office or hospital for some type of pain relief—even a surgery—to feel better. And then another attack could come, and another, driving […]

San Diego Life Sciences Roundup: Evofem, Cullgen, BrainLeap & More

Posted by |2019-04-11T19:51:44-07:00April 11th, 2019|

Locally based biotech companies receive fresh funding from investors. A software startup launches games that it says may help children with disorders that cause attention difficulties. Get the details on these developments and more in San Diego life sciences news: —Evofem Biosciences (NASDAQ: EVFM) struck a deal to raise up to $80 million in a […]

Jintel Health Taps Former Zimmer Biomet Exec Dvorak for CEO Post

Posted by |2019-04-10T11:02:48-07:00April 10th, 2019|

David Dvorak has been appointed chairman of the board and CEO of Jintel Health. Ping Zhang, founder of Richmond, CA-based Jintel, will become president of the company. Dvorak is the former chief executive of medical devices giant Zimmer Biomet (NYSE: ZBH). Jintel says it has developed technology uses analytics and machine learning for clinical and […]

Senators Grill Pharmacy Benefit Execs About Skyrocketing Drug Prices

Posted by |2019-04-09T17:15:20-07:00April 9th, 2019|

Executives from five of the companies that negotiate drug prices on behalf of insurers testified Tuesday before the Senate finance committee. It was the latest in a series of hearings centered on the rising cost of prescription medication, which has captured attention on both sides of the political aisle and is likely to become a […]

VC Trends in 2019: More Money, Fewer Deals But Women Still Get Less

Posted by |2019-04-08T20:01:50-07:00April 8th, 2019|

If you’ve been following venture capital trends, what you expected to happen in the first quarter of 2019 did: More money is being invested in fewer deals, and women founders still are getting less of it than men. Venture firms sent $32.6 billion into startups nationally during the first three months of 2019, the second […]

Ex-Seres Executive Roger Pomerantz Appointed ContraFect CEO

Posted by |2019-04-08T03:30:07-07:00April 5th, 2019|

Roger Pomerantz is now chairman and CEO of infectious diseases drug developer ContraFect (NASDAQ: CFRX). He succeeds Steven Gilman, who is retiring. Pomerantz has been vice chairman of Yonkers, NY-based ContraFect for five years. He was also CEO of Cambridge, MA-based microbiome drug developer Seres Therapeutics (NASDAQ: MCRB) from 2014 until January of this year. […]

Load More Posts